Table 1.
Therapeutic strategy | Drug/method | Name of agent | Binding ligand | Target marker | Therapeutic effect | Imaging modality | Ref |
---|---|---|---|---|---|---|---|
Chemical therapy | Rapamycin | RAP@Fe3O4‐PDA‐CD‐PEG‐PEI‐Profilin‐1‐Cy5.5 nanoparticles | Anti‐profilin‐1 | Profilin‐1, vascular smooth muscle cells (VSMCs) | Anti‐inflammatory and stabilized plaque | Magnetic resonance imaging (MRI)/Near‐infrared fluorescent (NIRF) | [38] |
Rapamycin | Rap/Fe3O4@VHP‐Lipo | VHPKQHR (VHP) peptide | Vascular cell adhesion molecule‐1 (VCAM‐1) | Reduce plaque and lower blood | MRI/Fluorescence bimodal imaging | [68] | |
Fumagillin | αvβ3‐targeted SPIONs | Peptidomimetic vitronectin antagonist | αvβ3‐integrin, VSMCs | Inhibit angiogenesis | MRI | [39b] | |
Fumagillin; Atorvastatin | αvβ3‐targeted SPIONs | Peptidomimetic αvβ3‐integrin antagonist | αvβ3‐integrin, VSMCs | Inhibit angiogenesis; Lower blood lipid |
MR molecular imaging |
[39a] | |
Dexamethasone (DEXA) | SPION‐DEXA | / | / | Anti‐inflammatory | MRI | [73] | |
α‐tocopherol prostacyclin |
IONP‐loaded Solid lipid nanoparticles | / | Platelet | Inhibit platelet aggregation | MRI | [62] | |
α‐tocopherol | P3‐functionalized NE‐SPIO‐PEG | Fully Human scFv‐Fc Antibody(P3) | Galectin 3, Macrophage | Antioxidation | MRI | [74] | |
Protocatechuic acid | MNP‐DEX/PCA | Dextran | Dectin‐1, Macrophage | Anti‐inflammatory | MRI | [54a] | |
Curcumin | SDP‐VCAM‐1/Cur/Cy5.5 | VCAM‐1 targeted peptide | VCAM‐1 | Scavenger ROS, anti‐inflammatory and antioxidant | MRI/Fluorescence imaging | [75] | |
Paclitaxel | USPIO + paclitaxel‐loaded polymer‐lipid hybrid theranostic nanoparticles conjugated with C11 (UP‐NP‐C11) | Polypeptide C11 | Collagen IV | Inhibit plaque progression and promote plaque stability | MRI | [45c] | |
CeO2 NPs | Iron oxide–cerium oxide core‐shell nanoparticles | / | / | Scavenger ROS, anti‐inflammatory and antioxidant | MRI | [76] | |
Chemical therapy | CeO2 NPs | CeO2·Fe3O4@LDH | / | / | Scavenger ROS, anti‐inflammatory and antioxidant | MRI | [63] |
Trisodium citrate‐coated cerium oxide | Chitosan Nanococktails containing both Ceria and SIONPs | / | / | Scavenger ROS, anti‐inflammatory and antioxidant | MRI | [77] | |
Physical stimulation therapy | Photodynamic therapy, chlorin‐based photosensitizer | CLIO‐TPC | Dextran | Dectin‐1, Macrophage | Ablation of macrophages | MRI/NIRF | [78] |
Photodynamic therapy, chlorin‐based photosensitizer | CLIO‐THPC | Dextran | Dectin‐1, Macrophage | Ablation of macrophages | MRI/NIRF | [79] | |
Photothermal therapy | Au‐coated IONP nanoclusters | Dextran | Dectin‐1, Macrophage | Ablation of macrophages | MRI/NIRF | [64] | |
Photothermal therapy | Ferrite‐encapsulated nanoparticles (PFH@PLGA/MnFe2O4‐Ram) | Ramucirumab (Ram) | Vascular endothelial growth factor receptor 2 (VEGFR2) on endothelial cells | Inhibit angiogenesis and promote plaque stability | MRI/Photoacoustic (PA)/Ultrasound (US) | [80] | |
Magnetic hyperthermia | SPIONs | / | / | Plaque Abrasion | MRI | [81] | |
Magnetic hyperthermia; Atorvastatin | pH‐responsive magnetic nanoplatforms (MMNS@AT‐CS‐DS) | Dextran sulfate (DS) | Class A scavenger receptors (SR‐A) on macrophage | Increase protective autophagy and regulate lipid metabolism | MRI | [82] | |
Ultrasound therapy, perfluorohexane (PFH) | SR‐A‐targeted phase‐transition nanoparticles (Fe‐PFH‐PLGA/CS‐DS NP) | Dextran sulfate | SR‐A on macrophage | Macrophage apoptosis | MRI/US | [65] | |
Ultrasound therapy, perfluorohexane | LIFU‐responsive nanomedicine (FPD@CD) | Dextran sulfate | SR‐A on macrophage | Macrophage apoptosis and stabilize and reduce plaque | MRI/NIRF | [83] | |
Physical stimulation therapy | Ultrasound therapy, perfluorohexane | Multifunctional pathology‐mapping theranostic nanoplatform (MPmTN) | PP1, cRGD peptide | SR‐A on macrophage, glycoprotein (GP) IIb/IIIa on activated platelets | Macrophage apoptosis and destroy thrombus | MRI/US | [35] |
Sonodynamic therapy, hematoporphyrin monomethyl ether (HMME) | Ultrasound‐Responsive Ferrite‐Encapsulated Nanoparticles (PFP–HMME@PLGA/MnFe2O4–Ram) | Ramucirumab | VEGFR2 on endothelial cells | Inhibit angiogenesis and promote plaque stability | MRI/PA/US | [69] | |
Biologic therapy | High‐Density‐Lipoprotein (HDL)‐mimics | High‐Density Lipoprotein‐like Magnetic Nanostructures (HDL‐MNS) | Apolipoprotein A1 | Macrophage | Reverse cholesterol transport | MRI | [84] |
HDL‐mimics | Dual‐targeted HDL‐mimicking nanoparticles | Mannose, triphenyl‐phosphonium | Macrophage, mitochondria | Lipid Removal | MRI | [61] | |
Gene therapy | LV / MNPs | / | Native endothelium | Overexpression of therapeutic genes eNOS and VEGF, improve vascular function | MRI | [71] | |
Gene therapy | PEI‐SPION/siRNA | / | Macrophage | Induce siRNA‐mediated target gene silencing | MRI | [85] | |
Interleukin 10 (IL10) | IL 10/IONP‐loaded cRGD | cRGD peptide | αvβ3‐integrin | Anti‐inflammatory | MRI | [72] | |
Cell transplantation | USPION‐labeled EPCs | / | / | Repair endothelial damage and prevent atherosclerosis | MRI | [86] | |
Phosphatidylserine | Phosphatidylserine‐presenting liposomes | Phosphatidylserine | Macrophage | Anti‐inflammatory | MRI | [87] |